Venetoclax combined with decitabine or azacitidine in treatment-naive . . . The data cutoff date for this analysis was July 7, 2017 Sixty patients received venetoclax 400 mg (29 with azacitidine, 31 with decitabine), 74 received venetoclax 800 mg (37 each azacitidine or decitabine), and 11 received venetoclax 1200 mg (6 azacitidine, 5 decitabine)
Ten-day Decitabine with Venetoclax in Acute Myeloid Leukemia: A Single . . . Our results show that combining 10-day decitabine with venetoclax is an effective and safe strategy for patients older than 60 years with untreated acute myeloid leukemia (AML), as well as those with previously treated disease To our knowledge, this is the first report of a prospective trial venetoclax with a hypomethylating agent in relapsed
Venetoclax combined with decitabine or azacitidine in . . . - PubMed During dose escalation, oral venetoclax was administered at 400, 800, or 1200 mg daily in combination with either decitabine (20 mg m 2, days 1-5, intravenously [IV]) or azacitidine (75 mg m 2, days 1-7, IV or subcutaneously) In the expansion, 400 or 800 mg venetoclax with either hypomethylating agent (HMA) was given
10-day decitabine with venetoclax for newly diagnosed intensive . . . The phase 3, randomised, VIALE-A trial reported improved overall survival in patients with treatment-naive AML treated with venetoclax and azacytidine (n=287) compared with azacitidine alone (n=146) 15,16 One retrospective study of venetoclax with decitabine in relapsed or refractory AML showed a CR or CRi rate of 52% (17 of 33 patients) and 1
Outcomes of 10-day decitabine with venetoclax for AML. Background: Venetoclax (VEN) + a hypomethylating agent (HMA) has improved outcomes for patients with acute myeloid leukemia (AML) VIALE-A showed improved overall response rate (ORR) and overall survival (OS) with VEN + HMA in newly diagnosed AML (ND AML); the complete remission (CR) rate was 36 7% and the median OS was 14 7 months
AML successful treatment - Mayo Clinic Connect Happy New Year! I want to share a happy treatment update for my wonderful response to Venetoclax and Dacogen (similar to Vidaza) for treatment of my AML When I was diagnosed 3 years ago I was considered too old for transplant at age 78 here at the Mayo Clinic I went into remission after my first cycle of treatment and have now stayed in
Low-Dose Weekly Decitabine and Venetoclax in TP53-Mutated Myeloid . . . Decitabine (Dec) and Azacitidine (Aza) that target DNA methyltransferase 1 (DNMT1) are hypomethylating agents (HMAs) approved to treat acute myel Amit Verma, Ira Braunschweig, Yogenthiran Saunthararajah, Mendel Goldfinger; Low-Dose Weekly Decitabine and Venetoclax in TP53-Mutated Myeloid Malignancies Blood 2021; 138 (Supplement 1):
Calendario